Health Care

Equillium’s execs are buying big stock options, signaling strong confidence in a 2026 clinical milestone and a potential rally for investors.

Explore how aTyr Pharma’s CEO, CFO, and General Counsel’s new option grants could trigger major dilution and impact stock value—key insights for investors.

Insider buying by Edwards Lifesciences’ chief valuation pro signals confidence amid a near 52‑week high and potential JenaValve deal, boosting investor optimism.

Kevin McCulloch’s 15,000‑share sale at Xeris Biopharma is a routine 10b‑5 plan liquidity move, not a signal of weakness amid strong revenue outlook and 14.27% monthly gains.

CEO’s 125k‑share option exercise signals Anavex stock is undervalued—insider confidence amid FDA milestone boosts buy‑the‑dip sentiment.

Oncolytics insider buying signals confidence: SVP Lee Chan Henry’s recent $331.76 ADS purchase, above market price, highlights optimism on the pelareorep pipeline and strategic shifts.

TG Therapeutics insiders buy shares amid volatility—CFO and CEO purchases hint at confidence in oncology pipeline and future upside.

Investor insight: Avidity Biosciences’ execs, led by Teresa McCarthy, sell‑to‑cover RSUs in a routine, schedule‑driven pattern that signals confidence in long‑term prospects while keeping liquidity tight.

BioVie’s insider buying spree shows execs betting on its biotech future, especially the SUNRISE‑PD study—potential upside amid steep stock decline.

Neumora Therapeutics sees a big insider option surge—board buys 4.65M shares, hinting at confidence in future milestones and potential upside.